BAC
Bank of America Corporation
BAC's fundamentals are strong: its operating margin rose 5 points to 35% and revenue grew 15%. At 12x earnings, it's trading in line with its usual 13x. Analysts expect earnings growth.
PSBD
Palmer Square Capital BDC Inc.
There isn't enough reported data to score PSBD yet.
BAC Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| N/A | |
| N/A |
BAC's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like BAC.
PSBD Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Healthy | |
| N/A | |
| N/A |
PSBD's profitability is currently healthy. There isn't enough data to rate its revenue. Free cash flow and net leverage aren't meaningful measures for financial services companies like PSBD.
BAC PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 9.4x | $39.50 | -22% |
| Forward | 10x | $50.51 | — |
| Current | 12x | $50.51 | — |
| Fair | 13x | $53.81 | +6.5% |
| Expensive | 15x | $62.23 | +23% |
Historical ranges are pointers, not guarantees.
BAC's PE is in its fair range at 12x. If earnings grow as analysts expect, today's price would be 10x next year's earnings, in its cheap range.
PSBD PE Valuation
PSBD has no meaningful PE right now: it lost money over the past year.
BAC Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| Moderate |
BAC has the edge over PSBD on the outlook, with more favorable earnings and revenue expectations.
PSBD Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Decline | |
| Stable | |
| Weakening | |
| Limited | |
| High |
Analysts expect PSBD's earnings and profitability to decline, with its revenue holding steady.
BAC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $4.92 | +17% |
| Q3 2026 | $4.19 | +14% |
| Q2 2026 | $4.34 | +27% |
| Q1 2026 | $4.02 | +20% |
| Q4 2025 | $3.81 | +19% |
| Q3 2025 | $3.66 | +33% |
| Q2 2025 | $3.41 | +20% |
| Q1 2025 | $3.35 | +16% |
| Q4 2024 | $3.21 | +4.2% |
BAC has the stronger earnings trend. Trailing diluted EPS is up 14% for BAC versus PSBD down 7.9%.
PSBD Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.54 | -12% |
| Q3 2023 | $3.42 | +$5.65 |
| Q2 2023 | $1.91 | +$3.78 |
| Q1 2023 | -$1.06 | -431% |
| Q4 2022 | -$2.31 | -485% |
PSBD earned $1.76 per share over the past year, down 7.9% from the year before.
BAC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $30B | +6.7% |
| Q2 2026 | $31.6B | +19% |
| Q1 2026 | $30.3B | +11% |
| Q4 2025 | $31.2B | +23% |
| Q3 2025 | $28.1B | +11% |
| Q2 2025 | $26.5B | +4.3% |
| Q1 2025 | $27.4B | +6% |
| Q4 2024 | $25.3B | +15% |
BAC has the edge over PSBD in the latest year-over-year revenue comparison.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 30% | -3.7 points |
| Q2 2026 | 37% | +7.6 points |
| Q1 2026 | 34% | +4.7 points |
| Q4 2025 | 40% | +12 points |
| Q3 2025 | 34% | +4.8 points |
| Q2 2025 | 29% | -0.7 points |
| Q1 2025 | 30% | +1.5 points |
| Q4 2024 | 28% | +14 points |
BAC's operating margin was 30% last quarter, down 3.7 points from the same quarter a year ago.
PSBD Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2022 | $765.3K | -89% |
| Q3 2021 | $7.2M | -59% |
| Q2 2021 | $7.4M | -78% |
PSBD's revenue has slid since its 2020 peak: $765,339 last quarter, down 89% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2022 | -883% | -948 points |
| Q4 2021 | 54% | -33 points |
| Q3 2021 | 66% | -29 points |
| Q2 2021 | 68% | N/A |
| Q1 2021 | 69% | N/A |
| Q3 2020 | 87% | N/A |
| Q2 2020 | 95% | N/A |
PSBD's operating margin was −883% last quarter, down 952 points from the same quarter a year ago, near the bottom of its range since 2020.
BAC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$6.5B | -114% |
| Q2 2026 | $29B | +$38.2B |
| Q1 2026 | $41.8B | +$44B |
| Q4 2025 | -$22.9B | -189% |
| Q3 2025 | $46.9B | +$84.2B |
| Q2 2025 | -$9.1B | -150% |
| Q1 2025 | -$2.2B | +$13.4B |
| Q4 2024 | $25.9B | -21% |
BAC's free cash flow was $41.4B over the past year, down 33% from the year before. Free cash flow isn't a meaningful measure for financial services companies like BAC.
PSBD Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $57.3M | +227% |
| Q2 2026 | $21.3M | -48% |
| Q1 2026 | $29.1M | -37% |
| Q4 2025 | $55.7M | +63% |
| Q3 2025 | $17.5M | +399% |
| Q2 2025 | $41M | +$41.5M |
| Q1 2025 | $46.4M | +$284.3M |
| Q4 2024 | $34.3M | +907% |
PSBD has the edge over BAC on cash flow, with more consistent year-over-year improvement.
BAC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1% | -72M shares |
| 1 year | -5.3% | -405M shares |
| 3 years | -11% | -854M shares |
| 5 years | -15% | -1.3B shares |
| Available history | -24% | -2.2B shares |
BAC has 7.2B diluted shares, down 5.3% from a year ago, with $25.6B in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $6B |
| Q2 2026 | $6B |
| Q1 2026 | $7.2B |
| Q4 2025 | $6.3B |
| Q3 2025 | $5.3B |
| Q2 2025 | $5.3B |
| Q1 2025 | $4.5B |
| Q4 2024 | $3.5B |
BAC spent $25.6B buying back its own shares over the past year, up 37% from the year before.
PSBD Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.5% | -461K shares |
| 1 year | -5.6% | -1.8M shares |
| 3 years | +24% | +5.9M shares |
| 5 years | -4.9% | -1.6M shares |
PSBD has the edge over BAC on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $5.2M |
| Q2 2026 | $4.1M |
| Q1 2026 | $1.6M |
| Q4 2025 | $7.6M |
| Q3 2025 | $4.7M |
| Q2 2025 | $4.2M |
| Q1 2025 | $1.5M |
| Q4 2024 | $765,047 |
PSBD spent $18M buying back its own shares over the past year, up 65% from the year before.
BAC Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 6.4x | High |
| Q2 2026 | 6.7x | High |
| Q1 2026 | 7.1x | High |
| Q4 2025 | 7.7x | High |
| Q3 2025 | 8.3x | High |
| Q2 2025 | 8.8x | High |
| Q1 2025 | 8.6x | High |
| Q4 2024 | 9.0x | High |
BAC's net debt is about 6.4 years of its operating earnings (EBITDA), down from 8.3 years a year ago. Net leverage isn't a meaningful measure for financial services companies like BAC.
PSBD Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2022 | 64.0x | High |
| Q4 2021 | 34.0x | High |
PSBD's net debt is more than 20 years of its operating earnings (EBITDA). Net leverage isn't a meaningful measure for financial services companies like PSBD.
BAC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 37.1 | Neutral |
| Stochastic | 4.9 | Oversold |
BAC's weekly RSI is 37 (neutral) and its Stochastic is 5 (oversold).
PSBD Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 41.7 | Neutral |
| Stochastic | 33.0 | Neutral |
PSBD's weekly RSI is 42 (neutral) and its Stochastic is 33 (neutral).
BAC PE vs Financial Services Sector
| Metric | BAC | Sector median | Relative |
|---|---|---|---|
| PE | 12x | 13x | 7.5% below |
| PE % | 40 | 63 | 23 pts below |
BAC is trading at 12x earnings, in line with the Financial Services sector's median of 13x.
PSBD PE vs Financial Services Sector
| Metric | PSBD | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 13x | — |
PSBD has no meaningful PE right now: it lost money over the past year.
BAC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $52.1 | 3% below |
| 20 week MA | $57.8 | 13% below |
| 50 week MA | $54.7 | 7.7% below |
| 100 week MA | $50.5 | 0% below |
| 200 week MA | $42.5 | 19% above |
PSBD has stronger trend alignment. BAC is above 1 of 5 weekly averages versus PSBD above 1 of 4.
PSBD Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $9.78 | 0.5% above |
| 20 week MA | $10.0 | 1.8% below |
| 50 week MA | $10.7 | 7.8% below |
| 100 week MA | $12.3 | 20% below |
PSBD has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 20% below its 100-week average.
BAC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $35.4 | $30.0 | -15% |
| 2021 | $30.0 | $44.4 | +48% |
| 2022 | $44.4 | $32.5 | -27% |
| 2023 | $32.5 | $33.7 | +3.7% |
| 2024 | $33.7 | $44.3 | +32% |
| 2025 | $44.3 | $56.2 | +27% |
| 2026 YTD | $56.2 | $50.5 | -10% |
BAC has the edge over PSBD on returns for 2026, with the stronger performance.
PSBD Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2024 | $16.4 | $15.5 | -5.3% |
| 2025 | $15.5 | $12.2 | -21% |
| 2026 YTD | $12.2 | $9.83 | -20% |
PSBD has finished every year since 2024 lower, and it's down 20% so far in 2026.